Access cutting-edge single ventricle heart disease treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access single ventricle heart disease specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related single ventricle heart disease treatment provided free
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Sponsor: Mezzion Pharma Co. Ltd
Check if you qualify for this single ventricle heart disease clinical trial in New Haven, CT
If you're searching for single ventricle heart disease treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced single ventricle heart disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.